INTRODUCTION
A variety of experimental procedures have been described for the induction of antigen-specific tolerance in neonates and adults (1) (2) (3) . In the immunocompetent adult, however, tolerance in-duction has been generally more difficult. Tolerance to foreign transplantation antigens or viral cytotoxic T lymphocyte (CTL) epitopes, for example, has previously been shown to be most effective primarily in models where hematopoietic or lymphoid ablation is followed by reconstitution with antigen-expressing bone marrow (BM)-derived antigen-presenting cells (APC) (4) (5) (6) (7) (8) . For autoimmune disease, a variety of studies have focused on the acquired induction of tolerance to autoantigens to prevent and/or ameliorate disease. For example, in murine models for multiple sclerosis and diabetes, prevention 213 of disease has been successfully accomplished with thymic, oral, and intravenous, high-dose administration of target autoantigens (9-1 1).
A strategy for the induction of clinically relevant tolerance can be indirectly derived from the original experiments demonstrating tolerance induction to foreign major histocompatibility complex (MHC) antigens via the injection of allogeneic hematopoietic cells into neonates (1) . In adults, however, attempts to induce tolerance to foreign grafts by injecting accessory celldepleted splenocytes (12, 13) or syngeneic transfected cells (14) has met with limited success. The advent of efficient methods for gene transfer into hematopoietic cells may in theory enable the expression of foreign antigens for the induction of tolerance via pathways similarly used for tolerance induction to naturally expressed determinants (e.g., MHC, Mls antigens) in bone marrow chimeras (15) (16) (17) (18) . Since such approaches have usually required some degree of myeloablation, a more desirable approach would be to adoptively transfer genetically modified peripheral APC (19) , which engraft more efficiently in the unconditioned host. An excellent candidate for such a strategy would be the peripheral B lymphocyte that has been described to possess immune-modulating characteristics. Previous studies have shown that, in some circumstances, antigen-presenting B cells are capable of inducing peripheral tolerance in mature, naive T cells in vivo (20) (21) (22) (23) , or even previously activated T cell clones in vitro (24) .
To test the potential for gene-transferring model target antigens into autologous APC, as well as the role of B cells in this process for the induction of specific immune tolerance, we created a recombinant, replication-defective retroviral vector for the expression of a foreign class II MHC-restricted immunodominant epitope. Our model determinant, residues 12-26 from cI A repressor protein (pl-102), contains both a T and B cell epitope (25, 26) and has been fused at the N terminus of a murine IgG H chain. Engineered Ig expressing heterologous epitopes has been described for the potentiation of peptidespecific immunity (27) , and we have recently expanded this approach by describing the tolerogenic properties of a soluble engineered 12-26-IgG fusion protein (28) . Here we show that bone marrow chimeras generated with retrovirally transduced marrow or even immunocompetent adult recipients infused with transduced mature, activated B lymphocytes are highly unresponsive to the peptide at both the humoral and cellular levels. The genetic transfer and expression of immunogenic epitopes or whole complex antigens by appropriate "nonprofessional" APC may have great utility for the specific elimination of undesirable immunity associated with autoimmune states (9-1 1), recombinant clotting factor administration (29) , and gene therapy protocols (30, 31) . [14] [15] [16] [17] [18] [19] [20] hr for the determination of proliferative responses. Cells were then harvested on glass fiber filters and incorporated 3H was detected using a direct ,8-counter (Packard, Matrix 9600). IL-2 and IL-4 cytokine production was quantitated by CTL line (CTLL) and CT.4S bioassays, respectively, using serial dilutions of LN or splenic culture supernatants and recombinant cytokine standards (Genzyme). Dilutions of anti-IL-2 mAb S4B6 and anti-IL-4 mAb 1iBi 1 (ATCC) were included to establish specificity. Murine IFN-,y was determined with a commercially available ELISA kit (Intertest-,y, Genzyme).
MATERIALS AND METHODS
RT-PCR and Immunologic Methods Detection of 12-26-IgG transcripts in transduced cell lines or hematopoietic tissue from BM-injected mice was performed with a 12-26 sequence RNA-PCR assay. Primers were designed to amplify 5' immunoglobulin leader sequence (VHS' primer, as above) and 3' 12-26 sequence, (3' pep primer): GGC AAC AGA AGC T?TT CAC TTC TTC TTC TCG TAT. Briefly, 1-5 ,ug of total RNA from various tissue was reverse transcribed (2 rounds) with AMV reverse transcriptase, dNTPs, and oligo dT and random hexamer primers (Invitrogen cDNA cycle kit) at 42°C. The resultant cDNA was amplified with 5' and 3' primers described above and Taq polymerase (Perkin-Elmer, Cetus). PCR conditions were 45 sec at 930C, 2 min at 47°C, and 2 min at 72°C for 3 5-40 cycles. Amplified DNA products were loaded (1/10-1/100 sample) onto 2% agarose/TBE gels and subsequently transferred onto nylon membranes for Southern blot analysis. 12-26 sequences were confirmed in RT-PCR-amplified DNA samples with a y-32P-labeled oligonucleotide (oligo Ig-one) encoding [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] but which does not overlap with the 3' PCR primer: TGA TCT ACT GCA GCT GGA GGA CGC GCG GCG G. Tissue RNA samples were compared via ,B-actin RT-PCR using commercially available primers (Stratagene). 12-26-IgG H chain protein was detected in culture supernatants of transduced cell lines or in sera of mice injected with gene-transferred cells, via its ability to bind to the NIP (5-iodo-4-hydroxy-3-nitrophenylacetyl) hapten using a modified NIP-binding ELISA (36) . Briefly, dilutions of culture supernatants or sera were incubated on ELISA plates coated with NIP-gelatin conjugate (10 ,ug/ml) and subsequently probed with goat anti-mouse IgG,-AP as a secondary reagent.
Standard curves with affinity-purified 12-26-IgG from supernatants of transfected J558L were used for quantitation.
RESULTS AND DISCUSSION
A recombinant retroviral vector (32) was modified by inserting a PCR-derived cDNA encoding the 12-26-IgG H chain sequence (Fig. IA) , and an ecotropic packaging line (F6P) was generated for the in vitro infection of cell lines and hematopoietic tissue via co-culture methods (33) (34) (35) . For initial studies, a variety of B cell lines at various stages of differentiation were transduced, including CH31 (immature), A20 (mature, activated), NS-1, and J558L (plasmacytomas). Intact proviral integration in transduced G418-resistant A20 cells could be verified by genomic Southern blotting using a DNA probe specific for [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] sequence (Fig. IA) . More importantly, 12-26-IgG heavy (H) chain can assemble with endogenous light chains in transduced B cell lines, which can be expressed as a membrane-surface protein (Fig. 1B) or secreted into cultured supernatants (50-80 ng/ml) in NS-1 and J558L myelomas. Immunoprecipitation of secreted 12-26-IgG and immunoblot analysis with a peptidespecific monoclonal antibody (B3.11) could directly demonstrate the expression of 12-26 peptide (Fig. IC) .
Although retrovirally synthesized gene products are expected to give rise primarily to processed peptides presented by MHC class I molecules, endogenously derived peptides can also be routed to endocytic class II MHC compartments in some cases (37) (38) (39) . Our initial hypothesis was that such a pathway would be enhanced for retrovirally encoded 12-26-IgG H chain due to the efficient nature of the immunoglobulin secretory pathway in targeting the endosomal compartment. To test for direct presentation of our model immunodominant class II-restricted peptide, we tested the ability of 12-26-IgG-transduced A20 cells to directly activate peptide-specific T cell hybrid 9C127, which recognizes 12-26 in the context of I-Ad (26) . Efficient presentation of endogenously synthesized peptide could be demonstrated, and this effect could be blocked with antibodies to CD4 or class II MHC molecules (Fig. IE) . These studies predict that, in vivo, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] (25, 28) . Analysis of hematopoietic tissue collected at sacrifice times using a peptide sequence-specific RT-PCR assay indicated that transcripts were expressed consistently and reproducibly in the bone marrow of all gene-transferred recipients, although variably in 'the thymus or spleen (a subset of these are illustrated in Fig. 1D (Fig. 2) , as were antipeptide antibody titers following priming and a secondary antigenic boost (Fig. 3) .
Since our BM transduction protocol targets containing IL-1, G-CSF, GM-CSF, M-CSF, and IL-6. Erythromyeloid colonies were grown with and without 1 mg/ml G418, and the percentages that were viable and neomycin-resistant (G418R) were counted after 7-10 days. BM recipients were conditioned with either 200 rads (Experiment 1) or 600 rads (Experiments 2-4). Detailed experimental results for Experiments 1 and 4 are presented in Fig. 3A (Fig. 4A) . [peptide] pM
(peptide] ,uM Furthermore, G418-resistant hybridomas could be generated from LPS-activated spleens of these tolerized mice by fusion with A20 lymphoma cells using polyethylene glycol (PEG). These hybrids were capable of stimulating peptide-specific 9C127 T cells directly (Fig. 4B) in these recipients is not known, although both are likely. Such long-term persistence (>3-6 months) is in agreement with similar results for injection of normal (41) as well as genetically modified, LPS-activated peripheral B cells (19) . These model studies outline a novel, efficient strategy by which foreign immunogens and target autoantigens may be delivered to the immune system in a tolerogenic manner as a soluble Ig fusion protein expressed in hematopoietic tissue. Genetic transfer of antigenic sequences either into a multipotential stem cell or in a (30) . Although immunity to low-level expression of viral proteins of first-generation, El-deleted adenovirus will undoubtedly be reduced with further deletion or modification of vectors, rejection of the foreign transgenes expressed by such vectors has been revealed as an even more significant obstacle (31) . Our data suggest that tolerogenic pretreatment of immunocompetent recipients with vector-transduced autologous APC expressing viral or foreign transgenes will allow for the prolonged expression and multiple administration of therapeutic transgenes in immunocompetent recipients without need for nonspecific immunosuppression.
Although solid evidence exists for the tolerogenic role of lymphohematopoietic APC in irradiated bone marrow (43) . Antigen presentation by resting B cells has thus far been useful for the induction of tolerance in naive recipients, but ineffective in primed (22) or allo-MHC-reactive recipients (23) unless anti-gp39 (CD40-ligand) antibodies were simultaneously injected to prevent up-regulation of B cell costimulatory function. Paradoxically, however, as in our experiments, costimulation-competent LPS blasts have also been shown to be efficient tolerogenic APC in vivo for antigen-naive recipients (22) or in vitro for previously activated T cell clones (24) . In parallel studies (44) Finally, modification of our protocol for the transduction of proliferating bone marrow-derived dendritic cells with peptide-Ig molecules may also allow for the efficient priming of Th and CTL for viral and tumor peptides and antigens. In summary, genetic transfer of antigenic sequences into peripheral APC, perhaps combined with transgenic expression of immune-modulating molecules such as CD95 (Fas ligand) (45) and (46) , is a very powerful approach for manipulating immune responses associated with autoimmunity, transplantation, and the administration of viral gene therapy vectors.
